Oxford Immunotec Global PLC (OXFD) Analysts See $-0.24 EPS

July 13, 2018 - By Michael Collier

Oxford Immunotec Global PLC (NASDAQ:OXFD) LogoInvestors sentiment decreased to 1.34 in Q1 2018. Its down 0.23, from 1.57 in 2017Q4. It fall, as 9 investors sold Oxford Immunotec Global PLC shares while 20 reduced holdings. 10 funds opened positions while 29 raised stakes. 23.37 million shares or 2.35% less from 23.93 million shares in 2017Q4 were reported.
Deutsche Comml Bank Ag has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Jpmorgan Chase & has invested 0% in Oxford Immunotec Global PLC (NASDAQ:OXFD). Legal General Gp Public Ltd Company holds 4,803 shares or 0% of its portfolio. Axa reported 580,614 shares. Minnesota-based First Light Asset Management Ltd Liability Com has invested 1.71% in Oxford Immunotec Global PLC (NASDAQ:OXFD). California State Teachers Retirement Sys reported 39,130 shares or 0% of all its holdings. Birchview Capital Lp has 177,303 shares for 1.45% of their portfolio. Endurant Cap Mgmt Limited Partnership owns 0.77% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 165,169 shares. Cortina Asset Mngmt Ltd owns 512,977 shares or 0.31% of their US portfolio. State Bank Of Ny Mellon Corporation has 69,231 shares. Goldman Sachs Group reported 31,340 shares stake. Wells Fargo And Mn invested in 0% or 41,646 shares. Northern has 0% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD). Moreover, Consonance L P has 2.66% invested in Oxford Immunotec Global PLC (NASDAQ:OXFD) for 2.34 million shares. Ellington Mngmt Lc invested in 15,900 shares.

Since February 15, 2018, it had 0 insider buys, and 2 selling transactions for $74,342 activity.

Analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to report $-0.24 EPS on August, 7.They anticipate $0.08 EPS change or 25.00 % from last quarter’s $-0.32 EPS. After having $-0.40 EPS previously, Oxford Immunotec Global PLC’s analysts see -40.00 % EPS growth. The stock increased 0.82% or $0.11 during the last trading session, reaching $13.55. About 43,464 shares traded. Oxford Immunotec Global PLC (NASDAQ:OXFD) has risen 0.28% since July 13, 2017 and is uptrending. It has underperformed by 12.29% the S&P500.

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for the management of immune-regulated conditions. The company has market cap of $350.69 million. The Company’s development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology. It currently has negative earnings. The firm develops its products using its T-SPOT technology platform, which enables the measurement of responses of specific immune cells to inform the diagnosis, prognosis, and monitoring of patients with immune-regulated conditions.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.